Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Accéder directement au contenu
Article Dans Une Revue Medicinal Chemistry Année : 2016

Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells

Résumé

The Bcl-2 family includes 26 proteins involved in apoptosis. Cancer cells can develop the ability to avoid apop-tosis through the upregulation and/or down regulation of such proteins Bax, Bcl-xL or Mcl-1, especially during chemore-sistance progress. These proteins engaged in a network of dynamic interactions that control apoptosis triggering have become attractive therapeutic targets in cancers including melanoma. Among them, the Bax/Bcl-xL interaction appears critical in maintaining mitochondria integrity. Therefore a series of mixed polyphenol-heterocyclic molecules, were rationally designed by molecular docking as Bax/Bcl-xL inhibitors. It has been screened against B16-F10 melanoma cancer cells for a preliminary investigation of their cytotoxicity. All these compounds exhibited a significant cytotoxicity against these cancer cells, in the 0.3-6 μM range. A pyrazole-type molecule, which had a submicromolar IC 50 value with an excellent selectivity index (14), is the most promising derivative for further development.

Domaines

Cancer
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-01406309 , version 1 (01-12-2016)

Identifiants

  • HAL Id : inserm-01406309 , version 1
  • PUBMED : 26825069

Citer

Duc Duy Vo, Isabelle Rouaud, Françoise Lohézic-Le Dévéhat, Fabien Gautier, Sophie Barillé-Nion, et al.. Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells. Medicinal Chemistry, 2016. ⟨inserm-01406309⟩
97 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More